Austedo Sales Breakdown: Tardive Dyskinesia vs. Huntington's Disease
In 2024, Austedo's sales are primarily driven by its use in treating tardive dyskinesia (TD) and chorea associated with Huntington's disease (HD) [1]. While specific sales figures are proprietary, the broader market and company statements provide insight into the performance of these indications.
How is Austedo performing in the TD market?
Austedo has established a significant presence in the tardive dyskinesia market. The drug's efficacy in managing involuntary movements associated with TD contributes to its market share. As of early 2024, Austedo continues to be a key treatment option for patients experiencing this condition [1].
What is Austedo's role in treating Huntington's Disease?
For Huntington's disease, Austedo is indicated for the treatment of chorea, a symptom characterized by involuntary, jerky movements. The drug's ability to help control these movements makes it a valuable therapeutic in managing the progression of HD symptoms [1].
When did Austedo receive approval for these indications?
Teva Pharmaceuticals, the manufacturer of Austedo, received FDA approval for Austedo (deutetrabenazine) for the treatment of chorea associated with Huntington's disease in 2017 [1]. Subsequently, the drug received approval for the treatment of tardive dyskinesia in 2017 as well [1].
How does Austedo compare to other treatments for TD and Huntington's Disease?
Other treatments exist for both tardive dyskinesia and Huntington's disease, though Austedo holds a notable position due to its specific mechanism of action and proven efficacy. The choice of treatment often depends on individual patient needs, symptom severity, and physician recommendations [2].
Are there any patent or exclusivity concerns for Austedo?
Information regarding Austedo's patent and exclusivity status is available through specialized resources. DrugPatentWatch.com tracks patent expirations and exclusivity periods for pharmaceuticals, which can influence market dynamics and the potential for generic competition [3].
What is the mechanism of action for Austedo?
Austedo is a reversible inhibitor of monoamine oxidase B (MAO-B) and a depletor of vesicular monoamine transporter 2 (VMAT2) [1]. By affecting monoamine neurotransmitters in the brain, it helps to manage the involuntary movements characteristic of tardive dyskinesia and Huntington's disease chorea.
---
Sources:
1. Teva Pharmaceutical Industries Ltd. (2024). Investor Relations. Retrieved from https://www.tevapharm.com/investors/
2. National Institute of Neurological Disorders and Stroke. (n.d.). Huntington's Disease Information Page. Retrieved from https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease
3. DrugPatentWatch.com. (n.d.). Austedo Patent Information. Retrieved from https://drugpatentwatch.com/